Chugai Pharmaceutical Co Ltd CHGCF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $32.43
- Day Range
- $29.75–29.75
- 52-Week Range
- $26.61–43.72
- Bid/Ask
- $29.69 / $32.46
- Market Cap
- $48.95 Bil
- Volume/Avg
- 2,614 / 2,409
Key Statistics
- Price/Earnings (Normalized)
- 22.60
- Price/Sales
- 6.83
- Dividend Yield (Trailing)
- 1.81%
- Dividend Yield (Forward)
- 1.87%
- Total Yield
- 1.81%
Company Profile
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan’s oncology market for the past decade, largely due to drugs licensed from its parent’s portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19 patients.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 7,604
- Website
- http://www.chugai-pharm.co.jp
Competitors
Valuation
|
Metric
|
CHGCF
|
4502
|
4568
|
|---|---|---|---|
Price/Earnings (Normalized) | 22.60 | 15.76 | 48.63 |
Price/Book Value | 4.51 | 0.90 | 6.23 |
Price/Sales | 6.83 | 1.54 | 6.57 |
Price/Cash Flow | 21.28 | 7.54 | 40.18 |
Price/Earnings
CHGCF
4502
4568
Financial Strength
|
Metric
|
CHGCF
|
4502
|
4568
|
|---|---|---|---|
Quick Ratio | 4.21 | 0.46 | 2.74 |
Current Ratio | 5.53 | 1.06 | 3.49 |
Interest Coverage | — | 1.93 | 11.76 |
Quick Ratio
CHGCF
4502
4568
Profitability
|
Metric
|
CHGCF
|
4502
|
4568
|
|---|---|---|---|
Return on Assets (Normalized) | 17.64% | 2.86% | 7.33% |
Return on Equity (Normalized) | 21.05% | 6.13% | 13.01% |
Return on Invested Capital (Normalized) | 20.98% | 4.78% | 11.32% |
Return on Assets
CHGCF
4502
4568
Drug Manufacturers - General Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Hvfdyyygd | Clnz | $726.1 Bil | |
JNJ
| Johnson & Johnson | Xffwjrdv | Cbk | $363.9 Bil | |
MRK
| Merck & Co Inc | Hjrxkcmh | Ztswp | $325.9 Bil | |
ABBV
| AbbVie Inc | Prbtfqrm | Tmhbz | $285.3 Bil | |
AZN
| AstraZeneca PLC ADR | Jhjmmxjlh | Rwcb | $238.5 Bil | |
NVS
| Novartis AG ADR | Mzcqmnd | Crrdl | $209.5 Bil | |
RHHBY
| Roche Holding AG ADR | Rhyzpclkt | Dgsy | $202.8 Bil | |
AMGN
| Amgen Inc | Bdvpmzqq | Wwr | $167.1 Bil | |
PFE
| Pfizer Inc | Dhhtvbkw | Rxwg | $160.8 Bil | |
SNY
| Sanofi SA ADR | Ydckvqrwq | Gcvyk | $124.8 Bil |